Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PBA
MCID: PSD088
MIFTS: 36

Pseudobulbar Affect (PBA)

Categories: Mental diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pseudobulbar Affect

About this section

MalaCards integrated aliases for Pseudobulbar Affect:

Name: Pseudobulbar Affect 52
Emotional Lability 52 29 6
Involuntary Emotional Expression Disorder 52 71
Pathological Crying and Laughing 52
Emotional Incontinence 52
Mood Swings 71
Pba 52

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Mental diseases
See all MalaCards categories (disease lists)


External Ids:

UMLS 71 C0085633 C3161187
Sources

Summaries for Pseudobulbar Affect

About this section
NIH Rare Diseases : 52 Pseudobulbar affect (PBA) is a condition characterized by episodes of sudden, uncontrollable and inappropriate episodes of crying or laughing. The condition can be embarrassing and disruptive to daily life. It typically occurs in people with certain neurological conditions or injuries that affect the way the brain controls emotion. It is common in stroke survivors and people with conditions such as dementia , multiple sclerosis , Lou Gehrig's disease (ALS) and traumatic brain injury . PBA is thought to affect more than one million people in the United States. The goal of treatment is to reduce the severity and frequency of emotional outbursts. Treatment may include the use of antidepressants and/or a combination of dextromethorphan and quinidine .

MalaCards based summary : Pseudobulbar Affect, also known as emotional lability, is related to progressive bulbar palsy and kuru, and has symptoms including mental and behavioral signs and symptoms, nervousness and demoralization and apathy. An important gene associated with Pseudobulbar Affect is CYP2D6 (Cytochrome P450 Family 2 Subfamily D Member 6). The drugs Rivastigmine and Fluoxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and amygdala.

Wikipedia : 74 Pseudobulbar affect (PBA), or emotional incontinence, is a type of emotional disturbance characterized... more...

Sources

Related Diseases for Pseudobulbar Affect

About this section

Diseases related to Pseudobulbar Affect via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 progressive bulbar palsy 11.6
2 kuru 11.3
3 colloid cysts of third ventricle 11.3
4 x-linked cerebral adrenoleukodystrophy 11.3
5 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 11.1
6 amyotrophic lateral sclerosis 1 10.6
7 lateral sclerosis 10.6
8 attention deficit-hyperactivity disorder 10.5
9 traumatic brain injury 10.5
10 multiple sclerosis 10.4
11 brain injury 10.4
12 huntington disease 10.3
13 oppositional defiant disorder 10.3
14 mood disorder 10.2
15 parkinson disease, late-onset 10.2
16 depression 10.2
17 triiodothyronine receptor auxiliary protein 10.1
18 hepatitis c virus 10.1
19 malaria 10.1
20 x-linked alport syndrome 10.1
21 thalassemia 10.1
22 alport syndrome 10.1
23 end stage renal failure 10.1
24 hypoglycemia 10.1
25 sickle cell disease 10.1
26 back pain 10.1
27 chronic pain 10.1
28 alzheimer disease 10.1
29 stroke, ischemic 10.1
30 acute cystitis 10.1
31 mental depression 10.1
32 cerebrovascular disease 10.1
33 substance abuse 10.0
34 endogenous depression 10.0
35 cardiac arrhythmia 9.9
36 meningioma, radiation-induced 9.9
37 meningioma, familial 9.9
38 anxiety 9.9
39 major depressive disorder 9.9
40 primary lateral sclerosis, adult, 1 9.9
41 major affective disorder 8 9.9
42 major affective disorder 9 9.9
43 respiratory failure 9.9
44 spinal meningioma 9.9
45 dementia 9.9
46 epilepsy 9.9
47 cerebral palsy 9.9
48 constipation 9.9
49 bipolar disorder 9.9
50 skull base meningioma 9.9

Graphical network of the top 20 diseases related to Pseudobulbar Affect:



Diseases related to Pseudobulbar Affect
Sources

Symptoms & Phenotypes for Pseudobulbar Affect

About this section

UMLS symptoms related to Pseudobulbar Affect:


mental and behavioral signs and symptoms, nervousness, demoralization and apathy, other signs and symptoms involving emotional state, signs and symptoms involving emotional state, pregnancy mood swing
Sources

Drugs & Therapeutics for Pseudobulbar Affect

About this section

Drugs for Pseudobulbar Affect (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
2
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
3
Polyestradiol phosphate Approved Phase 4 28014-46-2
4
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
5
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
6
Drospirenone Approved Phase 4 67392-87-4 68873
7
Desogestrel Approved Phase 4 54024-22-5 40973
8
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
9
Norepinephrine Approved Phase 4 51-41-2 439260
10
Lithium carbonate Approved Phase 4 554-13-2
11
Topiramate Approved Phase 4 97240-79-4 5284627
12
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
13
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
14
Suvorexant Approved, Investigational Phase 4 1030377-33-3
15
Promethazine Approved, Investigational Phase 4 60-87-7 4927
16
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
17
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
18
Quinidine Approved, Investigational Phase 4 56-54-2 441074
19
Citalopram Approved Phase 4 59729-33-8 2771
20
Allopurinol Approved Phase 4 315-30-0 2094
21
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
22
Daidzein Experimental Phase 4 486-66-8 5281708
23
Genistein Investigational Phase 4 446-72-0 5280961
24 Anticonvulsants Phase 4
25 Tranquilizing Agents Phase 4
26 Neuroprotective Agents Phase 4
27 Cholinesterase Inhibitors Phase 4
28 Antipsychotic Agents Phase 4
29 Estrogens Phase 4
30 Quetiapine Fumarate Phase 4 111974-72-2
31 Contraceptive Agents Phase 4
32 Contraceptives, Oral Phase 4
33 Estradiol 17 beta-cypionate Phase 4
34 Contraceptives, Oral, Combined Phase 4
35 Progestins Phase 4
36 Estradiol 3-benzoate Phase 4
37 Dacuronium Phase 4
38 Natriuretic Agents Phase 4
39 Mineralocorticoids Phase 4
40 Mineralocorticoid Receptor Antagonists Phase 4
41 Drospirenone and ethinyl estradiol combination Phase 4
42 diuretics Phase 4
43 Antiviral Agents Phase 4
44 N-monoacetylcystine Phase 4
45 Antidotes Phase 4
46 Expectorants Phase 4
47 Venlafaxine Hydrochloride Phase 4
48 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
49 Red Clover Phase 4
50 Phytoestrogens Phase 4

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
2 A Study to Assess the Safety, Tolerability and Effectiveness of Nuedexta (Dextromethorphan 20 mg/Quinidine 10 mg) in the Treatment of Pseudobulbar Affect (PBA) Completed NCT01799941 Phase 4 Nuedexta (DM 20 mg/Q 10 mg)
3 Double Blind Placebo Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings Completed NCT02078596 Phase 4 Divalproex
4 Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease Completed NCT00104442 Phase 4 Rivastigmine
5 A Comparative Efficacy of Low-dose Combine Oral Contraceptives Containing Desogestrel 150 mg and Drospirenone 3 mg on Premenstrual Symptoms Completed NCT01482338 Phase 4 EE 20 microgram with desogestrel 150 mg;EE 20 microgram with drospirenone 3 mg
6 Open-Label Study of N-Acetylcysteine in Children and Adolescents Ages 5-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT02357290 Phase 4 Open-label Treatment with N-Acetylcysteine
7 Treatment of Bipolar Type II Major Depression Completed NCT00602537 Phase 4 Venlafaxine;Lithium Carbonate
8 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
9 Impact of Phytoestrogens on Serum Lipids in Postmenopausal Women Completed NCT01497977 Phase 4 phytoestrogens;phytoestrogens
10 Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents Completed NCT00393978 Phase 4 Quetiapine and placebo;Quetiapine and Topiramate
11 A Prospective, Randomized, Multicenter, Open-Label, Pilot Study to Investigate Medication Adherence & Patient Reported Symptom Occurrence & Interference w/ Daily Life Comparing Envarsus XR® & Immediate Release Tacrolimus in Adult Renal Transplant Recipients (SIMPLE) Recruiting NCT03979365 Phase 4 Envarsus XR;Tacrolimus twice daily
12 A Double-Blind Sequential Parallel Study of Suvorexant (Belsomra) for the Treatment of Bipolar Depression With Insomnia Not yet recruiting NCT03764683 Phase 4 Suvorexant (Belsomra);Placebo
13 A Study to Assess Effectiveness, Safety, and Health-related Outcomes of NUEDEXTA® (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the Treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients Terminated NCT02496039 Phase 4 NUEDEXTA®
14 A Double-Blind, Placebo-Controlled Investigation Into the Safety and Efficacy of Escitalopram for Depression in Multiple Sclerosis Terminated NCT00151294 Phase 4 escitalopram oxalate antidepressant
15 Clinical Protocol of a Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Alzheimer's Disease Terminated NCT01832350 Phase 4 Nuedexta (20/10)
16 An Open Label, Naturalistic Study With Allopurinol Augmentation for Prevention of Mania in Bipolar Disorder Terminated NCT00732251 Phase 4 Allopurinol
17 A Phase 3 Study of the Use of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder Unknown status NCT01217775 Phase 3 PH80;Placebo intranasal spray
18 The Synergistic Use of Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in the Management of Severe Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial Unknown status NCT02488538 Phase 3 Combined oral contraceptives;Fluoxetine;Combined oral contraceptives placebo;Fluoxetine placebo
19 Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial Unknown status NCT02427334 Phase 3 Dienogest;Fluoxetine;Placebo
20 Does Adding Combined Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome? A Double Blind Placebo Controlled Study. Unknown status NCT02562053 Phase 3 Fluoxetine;Combined oral contraceptives;Placebo 1;Placebo 2
21 An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect. Completed NCT00056524 Phase 3 AVP-923
22 Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients Completed NCT00050232 Phase 3 AVP-923
23 A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis Completed NCT00021697 Phase 3 AVP-923
24 A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) Completed NCT00573443 Phase 3 dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Placebo
25 An Open Label Phase 3 Study of Fortigel Testosterone Gel 2% in Hypogonadal Males Completed NCT00522431 Phase 3 Testosterone
26 A Double-Blind, 40-Week Continuation Study Evaluating the Safety of Asenapine and Olanzapine in the Treatment of Subjects With Acute Mania Clinical Trial Protocol A7501007 (Secondary Title: ARES) Completed NCT00159783 Phase 3 asenapine;Olanzapine
27 A Double-Blind, 9-Week Extension Study Evaluating the Safety and Maintenance of Effect of Asenapine vs. Olanzapine in the Treatment of Subjects With Acute Mania Clinical Trial Protocol A7501006 (Secondary Title: ARES) Completed NCT00143182 Phase 3 Asenapine;Olanzapine
28 A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual Asenapine vs. Olanzapine and Placebo in In-Patients With an Acute Manic Episode Clinical Trial Protocol 7501005 (Secondary Title: ARES) Completed NCT00159796 Phase 3 Asenapine;Olanzapine;Placebo
29 A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual Asenapine vs. Olanzapine and Placebo in In-Patients With an Acute Manic Episode Clinical Trial Protocol 7501004 (Secondary Title: ARES) Completed NCT00159744 Phase 3 Asenapine;Olanzapine;Placebo
30 A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
31 The Impact of Sérélys PMS, a Herbal Remedy Based on Pollen Extraction and Saffron, on Symptoms of PMS: A Randomized, Double-blinded, Placebo Controlled Study Completed NCT03298607 Phase 3
32 Use of Acupuncture In Autistic Spectrum Disorder Completed NCT00346736 Phase 3
33 A Single-Blind Prospective Study of Quetiapine for the Treatment of Mood Disorders in Adolescents Completed NCT00221468 Phase 3 quetiapine
34 Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram Completed NCT00562861 Phase 2, Phase 3 citalopram + mood stabilizer;placebo + mood stabilizer
35 Fluoxetine for the Treatment of Major Depression in Youth With Bipolar Disorder _ Terminated NCT00005015 Phase 3 Fluoxetine
36 Treatment of Schizoaffective Disorder Using Mifepristone Terminated NCT00725270 Phase 2, Phase 3 Mifepristone;Placebo Oral Tablet
37 Optimal Hormone Replacement for Women With Premature Ovarian Insufficiency Withdrawn NCT02922348 Phase 3 Hormone Replacement Therapy;Combined Oral Contraceptives
38 Antibiotic Treatment and Intravenous Immunoglobulin Double-blind, Randomized, Placebo-controlled Trial for PANDAS Unknown status NCT01769027 Phase 2 Sertraline+Antibiotic (penicillin/azithromycin);Sertraline+placebo
39 A Pilot Study: Logan Basic Technique and Auxiliary Abdominal Contacts for Reducing Symptomatology of Primary Dysmenorrhea Unknown status NCT00740818 Phase 2
40 Double-Blind, Placebo-Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings Completed NCT00217932 Phase 2 Divalproex Sodium (Depakote)
41 Efficacy of Menopause Relief EP-40 - Fixed Combination of Cimicifuga EP-40 and Rhodiola EPR-7 Extracts in Women With Menopausal Symptoms: A Randomized, Double Blind, Placebo Controlled Study Completed NCT03461380 Phase 2
42 A Phase 2B Study to Determine the Dose Response Pharmacokinetics of TSX-002 (Testosterone) in Hypogonadal Males Completed NCT02222558 Phase 2 TSX-002
43 A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome Completed NCT01894958 Phase 2 NNZ-2566;Placebo
44 A Phase 2, Randomized, Double-blind, Dose Response Study of Oral Testosterone in Subjects With Hypogonadism Completed NCT01717768 Phase 2 TSX-002
45 A Double-Blind, Double-Dummy, Placebo-Controlled, Dose Ranging Study of 7.5, 15, and 30 mg of Sublingual Lobeline in Adult ADHD Patients Completed NCT00664703 Phase 2 Lobeline sulfate;Methylphenidate HCl;Placebo
46 A Double-blind Randomized Placebo-controlled Study of Aspirin and N-acetyl Cysteine as Adjunctive Treatments for Bipolar Disorder Patients (SMRI 11T-009) Completed NCT01797575 Phase 2 Aspirin;Sugar Pill
47 Impact of Nuedexta on Bulbar Physiology and Function in ALS Recruiting NCT03883581 Phase 1, Phase 2 dextromethorphan HBr and quinidine sulfate
48 Effect of Oral Magnesium Supplementation on Anesthesia and Postoperative Analgesia After Surgical Removal of the Lower Third Molars. Active, not recruiting NCT03398382 Phase 1, Phase 2
49 Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Quetiapine-Referenced, Fixed-Dose Study of Lu AA39959 in the Treatment of Depression in Patients With Bipolar I or II Disorder Terminated NCT00771134 Phase 2 Lu AA39959;Placebo;Quetiapine
50 Randomised, Double-blind, Parallel-group, Placebo-controlled, and Active Referenced Study of Lu AA34893 to Evaluate the Efficacy and Safety of Three Doses Lu AA34893 in the Treatment of Depression in Patients With Bipolar I or II Disorder Terminated NCT00622245 Phase 2 Lu AA34893;Quetiapine fumarate;Placebo

Search NIH Clinical Center for Pseudobulbar Affect

Sources

Genetic Tests for Pseudobulbar Affect

About this section

Genetic tests related to Pseudobulbar Affect:

# Genetic test Affiliating Genes
1 Emotional Lability 29
Sources

Anatomical Context for Pseudobulbar Affect

About this section

MalaCards organs/tissues related to Pseudobulbar Affect:

40
Brain, Breast, Amygdala, Heart, Temporal Lobe, Prostate, Bone Marrow
Sources

Publications for Pseudobulbar Affect

About this section

Articles related to Pseudobulbar Affect:

(show top 50) (show all 872)
# Title Authors PMID Year
1
High Sleep Disturbance and Longer Concussion Duration in Repeat Concussions. 61
30784317 2020
2
Parkinson's disease and spirituality. 61
32039874 2020
3
A comparison study assessing neuropsychological outcome of patients with post-operative pediatric cerebellar mutism syndrome and matched controls after proton radiation therapy. 61
31325031 2020
4
Neuropsychological group rehabilitation on neurobehavioral comorbidities in children with epilepsy. 61
31645316 2020
5
Emotional lability and irritability have specific associations with symptomatology in children with attention deficit hyperactivity disorder. 61
32014627 2020
6
Alternative DSM-5 Model for Personality Disorders Through the Lens of an Empirical Network Model. 61
31928067 2020
7
Monoaminergic Genetic Variants, Prefrontal Cortex-Amygdala Circuit, and Emotional Symptoms in Children With ADHD: Exploration Based on the Gene-Brain-Behavior Relationship. 61
31910717 2020
8
Neurobehavioural complications of sleep deprivation: Shedding light on the emerging role of neuroactive steroids. 61
31505075 2020
9
Pharmacotherapy for the Pseudobulbar Affect in Individuals Who Have Sustained a Traumatic Brain Injury: a Systematic Review. 61
31942705 2020
10
Financial hardship among individuals with serious mental illness. 61
31690462 2019
11
F-18 FDG PET brain imaging in symptomatic arthroprosthetic cobaltism. 61
31863138 2019
12
Mindfulness and negative affectivity in real time: a within-person process model. 61
30909800 2019
13
A Kyojo's Delirium: Insights into the Inner Mind of a Young Asian Female Patient. 61
31886098 2019
14
How are early maladaptive schemas and DSM-5 personality traits associated with the severity of binge eating? 61
31733127 2019
15
Selective Serotonin Reuptake Inhibitor Monotherapy for Anxiety Disorders in Children and Adolescents with Autism Spectrum Disorder: A Chart Review. 61
31295004 2019
16
Establishing a Pediatric Acute-Onset Neuropsychiatric Syndrome Clinic: Baseline Clinical Features of the Pediatric Acute-Onset Neuropsychiatric Syndrome Cohort at Karolinska Institutet. 61
31170007 2019
17
[Social Behavioral Problems after Brain Injury]. 61
31588053 2019
18
The Relationship Between Neuropsychological Deficits and Emotional Lability in Adults With ADHD. 61
29890879 2019
19
Acute Phase Treatment Outcomes of Electroconvulsive Therapy in Adolescents and Young Adults. 61
30562200 2019
20
The role of overlapping excitatory symptoms in major depression: are they relevant for the diagnosis of mixed state? 61
31132693 2019
21
Psychiatric Adverse Events in Patients Taking Isotretinoin as Reported in a Food and Drug Administration Database From 1997 to 2017. 61
31268488 2019
22
Posterior fossa syndrome and increased mean diffusivity in the olivary bodies. 61
31349230 2019
23
The Man Who Saw Things on Carvedilol. 61
31250422 2019
24
Personality traits as an organizing framework for personality pathology. 61
31309725 2019
25
Patterns of response to antidepressants in major depressive disorder: Drug resistance or worsening of depression are associated with a bipolar diathesis. 61
31227264 2019
26
Is Emotional Lability Distinct From "Angry/Irritable Mood," "Negative Affect," or Other Subdimensions of Oppositional Defiant Disorder in Children With ADHD? 61
26842831 2019
27
Autosomal Dominant Gene Negative Frontotemporal Dementia-Think of SCA17. 61
30617627 2019
28
Genome-wide analysis of emotional lability in adult attention deficit hyperactivity disorder (ADHD). 61
31085060 2019
29
Predictive utility of childhood diagnosis of ICD-10 hyperkinetic disorder: adult outcomes in the MTA and effect of comorbidity. 61
30232561 2019
30
Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype. 61
30716424 2019
31
Living kidney donor and recipient perspectives on their relationship: longitudinal semi-structured interviews. 61
30948607 2019
32
Pharmaceutical interventions for emotionalism after stroke. 61
30887498 2019
33
Evaluating a scale of excessive mind wandering among males and females with and without attention-deficit/hyperactivity disorder from a population sample. 61
30816143 2019
34
Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect. 61
30615021 2019
35
Differentiating bipolar disorder from borderline personality disorder: Diagnostic accuracy of the difficulty in emotion regulation scale and personality inventory for DSM-5. 61
30699870 2019
36
Dependency, mood instability, and inconsequence traits for discriminating borderline personality disorder. 61
30843964 2019
37
Borderline personality disorder diagnosis in a new key. 61
31827801 2019
38
Dependency, mood instability, and inconsequence traits for discriminating borderline personality disorder. 61
30994782 2019
39
[Depressive disorders and diabetes mellitus in children and adolescents]. 61
31464293 2019
40
The psychopharmacology of pseudobulbar affect. 61
31727215 2019
41
Inner Dialogical Communication and Pathological Personality Traits. 61
31379684 2019
42
Case report of severe psychiatric sequelae in a 16-year-old female following resection of a purely dopamine-secreting ganglioneuroma. 61
31394385 2019
43
Alice in Wonderland Syndrome as a Presenting Manifestation of Creutzfeldt-Jakob Disease. 61
31143156 2019
44
The effect of memantine in adult patients with attention deficit hyperactivity disorder. 61
30663824 2019
45
Pseudobulbar Affect in Parkinsonian Disorders: A Review. 61
30732430 2019
46
The effects of emotional lability, mind wandering and sleep quality on ADHD symptom severity in adults with ADHD. 61
30384113 2019
47
Paediatric Moyamoya Disease and Tourette's Syndrome: An Unusual Association Responding Favourably to Direct and Indirect Cerebral Revascularisation Surgery. 61
31590166 2019
48
Negative Affect, Type D Personality, Quality of Life, and Dysfunctional Outcomes of Total Knee Arthroplasty. 61
30719200 2019
49
Efficacy of amantadine on behavioural problems due to acquired brain injury: A systematic review. 61
31250669 2019
50
Patient experiences of living with chronic leg ulcers and making the decision to seek professional health-care. 61
30724122 2019
Sources

Variations for Pseudobulbar Affect

About this section

ClinVar genetic disease variations for Pseudobulbar Affect:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 46;XY;t(9;11)(q34;p11.2)dnTranslocation Pathogenic 267847
2 46;XX;t(2;11)(q11.2;p13)dnTranslocation Pathogenic 267861
Sources

Expression for Pseudobulbar Affect

About this section
Search GEO for disease gene expression data for Pseudobulbar Affect.
Sources

Pathways for Pseudobulbar Affect

About this section
Sources

GO Terms for Pseudobulbar Affect

About this section
Sources

Sources for Pseudobulbar Affect

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....